Close
ACHEMA MIDDLE EAST 2026

World Cell & Gene Therapy Supply Chain To Hit $3.12b By 2031

The global cell and gene therapy (CGT) supply chain and logistics industry is predicted to reach $3.12 billion by 2031, based on a market...

£277m Funding Set To Benefit UK Life Sciences Manufacturing

A £277 million joint government-industry finance package will assist four UK life sciences companies in moving forward with life sciences manufacturing initiatives. The Life Sciences...

Considerable Rise In Healthcare Deals Expected In 2023

Pharma companies with plenty of cash were on one side of a $200 billion patent cliff. On the other hand, there were a lot...

Significant M&A Agreements Are On The Horizon For 2023

According to EY's 2023 M&A Firepower report, the life sciences sector has record levels of deal-making Firepower, which measures a company's ability to undertake...

Cancer Treatment Rates In NHS Hit An All-Time High In 2022

The NHS has released encouraging statistics regarding cancer rates in the UK to kick off the new year. Over the past year, more patients...

Quality Assurance Advances In Pharmaceutical Manufacturing

The needs of manufacturing facilities, tools, and procedures must be suitable for this new environment as the focus of new drug research shifts toward...

India Keen To Establish National Database On Dosage Forms

In an effort to better inform and empower consumers, the Indian government has announced plans to create a comprehensive database on every medicinal composition...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...